SMITHKLINE BEECHAM AND JANSSEN, A JOHNSON & JOHNSON SUBSIDIARY, TO CO-PROMOTE SMITHKLINE BEECHAM'S PAXIL AND JANSSEN'S RISPERDAL IN U.S.
PHILADELPHIA, May 13 /PRNewswire/ -- SmithKline Beecham (NYSE: SBH) and Janssen Pharmaceutica Inc., a Johnson & Johnson (NYSE: JNJ) subsidiary, today announced an agreement to cooperate in the promotion of SmithKline Beecham's Paxil and Janssen's Risperdal to psychiatrists in the United States. Paxil (paroxetine hydrochloride), a selective serotonin reuptake inhibitor for the treatment of depression, was approved for U.S. marketing on Dec. 29, 1992. Risperdal (risperidone), a compound for the treatment of schizophrenia, is awaiting U.S. Food and Drug Administration approval. A new drug application was filed in April 1992, and was recently recommended unanimously for approval by the FDA Advisory Panel. "This partnership of two recognized leaders in the psychiatric field will help to better establish two very promising products, both of which are of significant interest to the psychiatric community," said Jerry Karabelas, president, SmithKline Beecham Pharmaceuticals-North America. Larry Pickering, President of Janssen Pharmaceutica, said: "We think this will be the most efficient way possible to help doctors understand these drugs and their role in psychiatric practice." Data from worldwide clinical trials of Paxil demonstrated that the drug is safe and effective in the treatment of depression. Paxil has been shown to have efficacy comparable to traditional antidepressants (such as the tricyclic agent imipramine); however, Paxil has a more favorable safety profile and is more easily tolerated by patients. In addition, Paxil was shown to be effective for the prevention of relapse during long-term treatment. Risperdal has been tested in clinical trials involving more than 2,000 patients with psychotic conditions. Risperdal blocks two receptor sites, serotonin and dopamine, that are associated with psychotic disorders. Risperdal has been approved in the United Kingdom and Canada and is expected to be marketed in both countries in the near future. SmithKline Beecham -- one of the world's leading healthcare companies -- discovers, develops, manufactures and markets human and animal pharmaceuticals, over-the-counter medicines, health related consumer products and clinical laboratory services. Janssen Pharmaceutica was founded in 1953 and has companies in 32 countries. It conducts research and markets products in a wide range of medical fields, including allergy, gastroenterology, anesthesiology, dermatology, oncology, psychiatry and infectious disease. /delval/ -0- 5/13/93 /CONTACT: Sharyn M. Arnold of SmithKline Beecham, 215-751-7074, or Jeffrey Leebaw of Janssen Pharmaceutica, 908-524-3350/ (SBH JNJ)
CO: SmithKline Beecham; Janssen Pharmaceutica, Inc. ST: Pennsylvania IN: MTC SU:
MJ-MK -- PH005 -- 7941 05/13/93 08:59 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||May 13, 1993|
|Previous Article:||U.S. STEEL MINING CO. TO SELL CUMBERLAND MINE TO CYPRUS COAL COMPANY|
|Next Article:||FLIR SYSTEMS INC. FILES FOR INITIAL PUBLIC OFFERING OF 2,300,000 SHARES OF COMMON STOCK|